Loading…
No business profile yet.
Size EirGenix (6589.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $427M, the 506th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$46.90 on 6 Nov 2026.
Performance Over six months the shares gained 1.9%, against -17.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 27.0% over the last twelve months (peer median +12.2%); the operating margin is -70.7% (peer median -5.0%).
Valuation It trades at 10.7× enterprise value to sales against a peer median of 5.4× (7th most expensive of 18).
Capital Return on invested capital runs 15.2 points below its cost of capital (5.0% WACC).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.21B | NT$1.01B | NT$1.01B | NT$1.02B | NT$1.48B |
| Revenue growth | — | 0% | -1% | -31% | — |
| Gross profit | NT$229M | NT$64.4M | NT$56.1M | NT$118M | NT$661M |
| EBITDA | -NT$598M | -NT$560M | -NT$652M | -NT$793M | -NT$126M |
| Net income | -NT$569M | -NT$761M | -NT$698M | -NT$915M | -NT$116M |
| Free cash flow | -NT$32.1M | -NT$903M | -NT$1.23B | -NT$1.56B | -NT$491M |
| Capital expenditure | NT$978M | NT$1.62B | NT$928M | NT$775M | NT$820M |
| Total debt | NT$1.76B | NT$1.71B | NT$901M | NT$465M | NT$459M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6589.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.5% | -13.2% | 6th highest of 21 |
| 6-month return | +1.9% | -17.4% | 4th highest of 20 |
| Distance from 52-week high | -44.4% | -35.2% | 9th lowest of 21 |
| Revenue growth (TTM) | +27.0% | +12.2% | 6th highest of 19 |
| Operating margin | -70.7% | -5.0% | 5th lowest of 19 |
| EV / Sales | 10.7× | 5.4× | 7th most expensive of 18 |
| ROIC minus cost of capital | -15.2 pp | -6.3 pp | 4th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | 10.7× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | 5.9× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | 12.1× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 2.3× | 18.2% | +7.3% |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | 22.4× | 31.8% | -3.3% |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | 12.1× | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | 11.4× | n/a | n/a |